Synthesis and anticancer activity of 2-cyano-2-(4-oxo-3-phenylthiazolidin-2-ylidene)-N-arylacetamides
DOI:
https://doi.org/10.14739/2409-2932.2020.2.207100Keywords:
4-thiazolidinones, Knoevenagel condensation, enamines, antitumor activityAbstract
Search for new biologically active compounds includes the directed design of molecules based on the so-called structural blocks – usually the privileged (structures, to which the 4-thiazolidinone cycle belongs. Therefore the development of methods for the synthesis of small "drug-like" molecules from 2-cyanomethylidene-4-thiazolidinone group as well as the study of their biological profile is an urgent task for modern medicinal chemistry.
Aim. To design and to the synthesis of novel 5-ylidene derivatives of 2-cyano-2-(4-oxo-3-phenylthiazolidin-2-ylidene)-N-arylacetamides. Study of the antitumor activity of synthesized compounds.
Materials and methods. Organic synthesis, study of the spectral characteristics of obtained 4-thiazolidinones (1H and 13C NMR spectroscopy, LC- MS spectrometry). In vitro antitumor activity study according to the DTP Program of the National Cancer Institute (USA).
Results. A number of 5-substituted 2-cyano-2-(4-oxo-3-phenylthiazolidin-2-ylidene)-N-arylacetamide derivatives had been synthesized. The structure and purity of the synthesized compounds were confirmed by the methods of elemental analysis, 1H, 13C NMR spectroscopy and LC-MS. The antitumor activity of some of the synthesized compounds was investigated on a panel of 59 human tumor cell lines representing nine neoplastic diseases.
Conclusions. Based on the C5 modification of the methylene group of the 4-thiazolidinone cycle, the target 5-ylidene and 5-aminomethylene-2-cyano-2-(4-oxo-3-phenylthiazolidin-2-ylidene)-N-arylacetamides had been synthesized. A hit-compound 2-cyano-2-[5-[(4-methoxyphenyl)methylene]-4-oxo-3-phenylthiazolidin-2-ylidene]-N-arylacetamide was identified that selectively inhibited the growth of some cell lines of CNS, kidney and breast cancers.
References
Ayati, A., Emami, S., Asadipour, A., Shafiee, A., & Foroumadi, A. (2015). Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. European Journal of Medicinal Chemistry, 97, 699-718. https://doi.org/10.1016/j.ejmech.2015.04.015
Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017). 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry. European Journal of Medicinal Chemistry, 140, 542-594. https://doi.org/10.1016/j.ejmech.2017.09.031
Stojanovic, M., Dzambaski, Z., Bondzic, B., Aleksic, J., & Baranac-Stojanovic, M. (2014). 4-Oxothiazolidines with Exocyclic C=C Double Bond(s): Synthesis, Structure, Reactions and Biological Activity. Current Or-ganic Chemistry, 18(9), 1108-1148. https://doi.org/10.2174/138527281809140624120436
Tripathi, A. C., Gupta, S. J., Fatima, G. N., Sonar, P. K., Verma, A., & Saraf, S. K. (2014). 4-Thiazolidinones: The advances continue. European Journal of Medicinal Chemistry, 72, 52-77. https://doi.org/10.1016/j.ejmech.2013.11.017
Jain, V. S., Vora, D. K., & Ramaa, C. S. (2013). Thiazolidine-2,4-diones: Progress towards multifarious applications. Bioorganic & Medicinal Chemistry, 21(7), 1599-1620. https://doi.org/10.1016/j.bmc.2013.01.029
Jain, A. K., Vaidya, A., Ravichandran, V., Kashaw, S. K., & Agrawal, R. K. (2012). Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorganic & Medicinal Chemistry, 20(11), 3378-3395. https://doi.org/10.1016/j.bmc.2012.03.069
Lesyk, R. B., & Zimenkovsky, B. S. (2004). 4-thiazolidones: Centenarian history, current status and perspectives for modern organic and medicinal chemistry. Current Organic Chemistry, 8(16), 1547-1577. https://doi.org/10.2174/1385272043369773
Kryshchyshyn, A. P. (2017). Frahment-oriientovanyi dyzain likarskykh zasobiv [Fragment-based drug design (FBDD)]. Zhurnal orhanichnoi ta farmatsevtychnoi khimii, 15(1), 28-44. [in Ukrainian]. https://doi.org/10.24959/zofh.17.913
Morphy, R., & Rankovic, Z. (2005). Designed multiple ligands. An emerging drug discovery paradigm. Journal of Medicinal Chemistry, 48(21), 6523-6543. https://doi.org/10.1021/jm058225d
Morphy, J. R., & Harris C. J. (Eds.). (2012). Designing multi-target drugs. Royal Society of Chemistry.
Zhang, W. L., Pei, J. F., & Lai, L. H. (2017). Computational Multitarget Drug Design. Journal of Chemical Information and Modeling, 57(3), 403-412. https://doi.org/10.1021/acs.jcim.6b00491
Bolognesi, M. L., & Cavalli, A. (2016). Multitarget Drug Discovery and Polypharmacology. Chemmedchem, 11(12), 1190-1192. https://doi.org/10.1002/cmdc.201600161
Shaveta, Mishra, S., & Singh, P. (2016). Hybrid molecules: The privileged scaffolds for various pharmaceuticals. European Journal of Medicinal Chemistry, 124, 500-536. https://doi.org/10.1016/j.ejmech.2016.08.039
Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017b). Recent developments with rhodanine as a scaffold for drug discovery. Expert Opinion on Drug Discovery, 12(12), 1233-1252. https://doi.org/10.1080/17460441.2017.1388370
Kryshchyshyn, A., Roman, O., Lozynskyi, A., & Lesyk, R. (2018). Thiopyrano 2,3-d Thiazoles as New Efficient Scaffolds in Medicinal Chemistry. Scientia Pharmaceutica, 86(2), Article Unsp 26. https://doi.org/10.3390/scipharm86020026
Tao, Z. Q., Gomha, S. M., Badrey, M. G., El-Idreesy, T. T., & Eldebss, T. M. A. (2018). Novel 4-Heteroaryl-antipyrines: Synthesis, Molecular Docking, and Evaluation as Potential Antibreast Cancer Agents. Journal of Heterocyclic Chemistry, 55(10), 2408-2416. https://doi.org/10.1002/jhet.3305
Kumar, R. & Patil, S. (2017). Biological prospective of 4-thiazolidinone: a re-view. Hygeia: Journal for Drugs and Medicines, 9(1), 80-97. https://doi.org/10.15254/H.J.D.Med.9.2017.166
Radwan, M. A. A., Ragab, E. A., Sabry, N. M., & El-Shenawy, S. M. (2007). Synthesis and biological evaluation of new 3-substituted indole derivatives as potential anti-inflammatory and analgesic agents. Bioorganic & Medicinal Chemistry, 15(11), 3832-3841. https://doi.org/10.1016/j.bmc.2007.03.024
Musini, V. M., Rezapour, P., Wright, J. M., Bassett, K., & Jauca, C. D. (2012). Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database of Systematic Reviews(8), Article Cd003825. https://doi.org/10.1002/14651858.CD003825.pub3
Galletti, F., Strazzullo, P., Barba, G., Cappuccio, F. P., Iacone, R., & Mancini, M. (1991). Diuretic therapy for mild hypertension – a comparison of the metabolic effects of etozoline and chlorthalidone during long-term treatment. Current Therapeutic Research-Clinical and Experimental, 50(2), 159-166.
Fisher, R., & Blum, D. (1995). Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia, 36, S105-S114. https://doi.org/10.1111/j.1528-1157.1995.tb05993.x
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (1996). Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. Epilepsy Research, 25(3), 299-319. https://doi.org/10.1016/s0920-1211(96)00081-2
Kaminskyy, D., Gzella, A. K., & Lesyk, R. (2014). Cyclocondensation of thi-oamides and haloacetic acid derivatives provides only 4-thiazolidinones; isomeric 5-thiazolidinones were not observed. Synthetic Communications, 44(2), 231-236. https://doi.org/10.1080/00397911.2013.800551
El-Desoky, S. I., Bondock, S. B., Etman, H. A., Fadda, A. A., & Metwally, M. A. (2003). Synthesis of some new thiazole derivatives of pharmaceutical interest. Sulfur Letters, 26(3), 127-135. https://doi.org/10.1080/0278611031000095331
Fadda, A. A., Bondock, S., Rabie, R., & Etman, H. A. (2008). Cyanoacetamide derivatives as synthons in heterocyclic synthesis. Turkish Journal of Chemistry, 32(3), 259-286.
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigrowolff, A., Graygoodrich, M., Camp-bell, H., Mayo, J., & Boyd, M. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor-cell lines. Journal of the National Cancer Institute, 83(11), 757-766. https://doi.org/10.1093/jnci/83.11.757
Boyd, M. R., & Pauli, K. D. (1995). Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Research, 34(2), 91-109. https://doi.org/10.1002/ddr.430340203
Boyd, M. R. (1997). The NCI in vitro anticancer drug discovery screen. In Anticancer Drug Development Guide (pp. 23-42). Humana Press, Totowa, NJ.
Shoemaker, R. H. (2006). The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer, 6(10), 813-823. https://doi.org/10.1038/nrc1951
Farag, A. M., Dawood, K. M., & Elmenoufy, H. A. (2004). A convenient route to pyridones, pyrazolo 2,3-a pyrimidines and pyrazolo 5,1-c triazines incorporating antipyrine moiety. Heteroatom Chemistry, 15(7), 508-514. https://doi.org/10.1002/hc.20046
Rostom, S. A. F. (2006). Synthesis and in vitro antitumor evaluation of some indeno 1,2-c-pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorganic & Medicinal Chemistry, 14(19), 6475-6485. https://doi.org/10.1016/j.bmc.2006.06.020
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
